){kind=logo}
Loeb & Loeb LLP is pleased to announce that FDA Regulatory and Compliance partner Scott Liebman will be speaking at the FDLI’s Advertising and Promotion Conference on a session titled, “The False Claims Act and the First Amendment."
From event website:
Keeping pace with evolving and often uncertain legal requirements can prove treacherous, and the consequences of misapplying the law have never been more significant. Those in the regulatory, legal, and marketing departments of medical product companies are invited to learn the do’s and don’ts of 2015 at the 26th Annual Advertising and Promotion Conference.
This annual event brings together the regulated industries and the regulators responsible for overseeing the advertising and promotion of prescription drugs, medical devices, biologics, and animal drugs. Representatives from all four of FDA’s medical product centers (the Center for Biologics Evaluation and Research, the Center for Drug Evaluation and Research, the Center for Devices and Radiological Health, and the Center for Veterinary Medicine), the U.S. Department of Health and Human Services Office of the Inspector General, the U.S. Department of Justice Consumer Protection Branch, and the Federal Trade Commission will provide you with the latest information on policy and enforcement activities, recommendations for approaching the gray areas of advertising and promotion, and much more. Industry experts will explore the uncharted territory of biosimilar and mobile medical application advertising, examine the latest rules affecting social media promotions, dissect recent court decisions, and provide practical takeaways. This event will provide both a broad and deep understanding of how to advertise and promote in a highly regulated environment.
From event website:
Keeping pace with evolving and often uncertain legal requirements can prove treacherous, and the consequences of misapplying the law have never been more significant. Those in the regulatory, legal, and marketing departments of medical product companies are invited to learn the do’s and don’ts of 2015 at the 26th Annual Advertising and Promotion Conference.
This annual event brings together the regulated industries and the regulators responsible for overseeing the advertising and promotion of prescription drugs, medical devices, biologics, and animal drugs. Representatives from all four of FDA’s medical product centers (the Center for Biologics Evaluation and Research, the Center for Drug Evaluation and Research, the Center for Devices and Radiological Health, and the Center for Veterinary Medicine), the U.S. Department of Health and Human Services Office of the Inspector General, the U.S. Department of Justice Consumer Protection Branch, and the Federal Trade Commission will provide you with the latest information on policy and enforcement activities, recommendations for approaching the gray areas of advertising and promotion, and much more. Industry experts will explore the uncharted territory of biosimilar and mobile medical application advertising, examine the latest rules affecting social media promotions, dissect recent court decisions, and provide practical takeaways. This event will provide both a broad and deep understanding of how to advertise and promote in a highly regulated environment.